IMS 2022 | MagnetisMM-7: elranatamab vs lenalidomide following autoHSCT in MRD-positive newly diagnosed myeloma
Maria-Victoria Mateos
• 25 Aug 2022
Maria-Victoria Mateos, MD, PhD, University of Salamanca, Salamanca, Spain, comments on the design and aims of MagnestisMM-7 (NCT05317416), a Phase III study comparing elranatamab versus lenalidomide in patients with newly diagnosed multiple myeloma who are MRD-positive following autologous hematopoietic stem cell transplantation (autoHSCT), with progression-free survival (PFS) and MRD conversion rate at one year as the primary endpoints of this study. This interview took place at the 19th International Myeloma Society Meeting (IMS) held in Los Angeles, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
